Search research articles
Contact Us
Filters
Showing results (51-60 of 92) with videos related to
Page
of 10
Sort By:
Cancer Chemotherapy and Pharmacology
|
December 24, 2014
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules
P Hamberg, R H J Mathijssen, P de Bruijn, et al.
British Journal of Cancer
|
April 21, 2011
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
N Penel, M V Glabbeke, S Mathoulin-Pelissier, et al.
British Journal of Cancer
|
June 10, 2015
Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area
K Sideras, S J Bots, K Biermann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2010
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel
M H Strijbos, J W Gratama, P I M Schmitz, et al.
The Pharmacogenomics Journal
|
January 25, 2017
Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib
J S L Kloth, M C Verboom, J J Swen, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
June 13, 2008
Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma
A R Van Gool, R Verkerk, D Fekkes, et al.
British Journal of Cancer
|
December 25, 2013
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study
P Hamberg, M J Boers-Sonderen, W T A van der Graaf, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 19, 2018
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy
N Touati, P Schöffski, S Litière, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
F Duffaud, S Sleijfer, S Litière, et al.
Breast Cancer Research and Treatment
|
May 24, 2023
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
M K Bos, S W Lam, G Motta, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 92) with videos related to
Sort By:
Page
of 10
Cancer Chemotherapy and Pharmacology
|
December 24, 2014
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules
P Hamberg, R H J Mathijssen, P de Bruijn, et al.
British Journal of Cancer
|
April 21, 2011
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
N Penel, M V Glabbeke, S Mathoulin-Pelissier, et al.
British Journal of Cancer
|
June 10, 2015
Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area
K Sideras, S J Bots, K Biermann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2010
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel
M H Strijbos, J W Gratama, P I M Schmitz, et al.
The Pharmacogenomics Journal
|
January 25, 2017
Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib
J S L Kloth, M C Verboom, J J Swen, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
June 13, 2008
Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma
A R Van Gool, R Verkerk, D Fekkes, et al.
British Journal of Cancer
|
December 25, 2013
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study
P Hamberg, M J Boers-Sonderen, W T A van der Graaf, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 19, 2018
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy
N Touati, P Schöffski, S Litière, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
F Duffaud, S Sleijfer, S Litière, et al.
Breast Cancer Research and Treatment
|
May 24, 2023
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
M K Bos, S W Lam, G Motta, et al.
Page
of 10